A large French study has shown that the vast
majority of people living with HIV who started treatment since 2000 in a
national cohort achieved a CD4 cell count in the normal range within three to
four years of starting treatment, while a large Italian study showed that
achieving a normal CD4 count on
Once daily dolutegravir superior to darunavir/ritonavir in 96-week follow up
Treatment with a triple
antiretroviral combination containing once-daily integrase inhibitor dolutegravir
(Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir
(Prezista) over 96 weeks of follow up,Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported at the Internatinal Congress of
Drug Therapy in HIV Infection in Glasgow last week.
Dolutegravir is also a component of
Once daily dolutegravir superior to darunavir/ritonavir in 96-week follow up
Treatment with a triple
antiretroviral combination containing once-daily integrase inhibitor dolutegravir
(Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir
(Prezista) over 96 weeks of follow up,Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported at the Internatinal Congress of
Drug Therapy in HIV Infection in Glasgow last week.
Dolutegravir is also a component of
One third of TB cases in Eastern European HIV clinic survey multi-drug resistant
Around one-third of people
living with HIV in Eastern Europe who were diagnosed with TB had multi-drug
resistant TB, according to the findings of a global study of TB/HIV management
in high- and middle-income countries. The findings of the study, conducted by EuroCoord, were presented by Anne Marie Efsen of the University of
